Datopotamab deruxtecan (Dato-DXd) in Chinese patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study
第一作者机构:[1]Shandong Canc Hosp, Jinan, Peoples R China
推荐引用方式(GB/T 7714):
Sun Yuping,Xiao Zuke,Cheng Ying,et al.Datopotamab deruxtecan (Dato-DXd) in Chinese patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study[J].JOURNAL OF CLINICAL ONCOLOGY.2024,42(16):
APA:
Sun, Yuping,Xiao, Zuke,Cheng, Ying,Li, Juan,Tu, Hai Yan...&Wu, Yi-Long.(2024).Datopotamab deruxtecan (Dato-DXd) in Chinese patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study.JOURNAL OF CLINICAL ONCOLOGY,42,(16)
MLA:
Sun, Yuping,et al."Datopotamab deruxtecan (Dato-DXd) in Chinese patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study".JOURNAL OF CLINICAL ONCOLOGY 42..16(2024)